Letrozole: Present and future role in the treatment of breast cancer

Surabhi Amar, Vivek Roy, Edith A. Perez

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

State of the art hormonal therapy for women with breast cancer has evolved over the last few years. Tamoxifen used to be the gold standard for adjuvant treatment of postmenopausal women with hormone-sensitive early breast cancer and also for patients with metastatic disease in whom hormonal manipulation was considered, but the introduction of third generation aromatase inhibitors has changed this concept. This article discusses the clinical implications of recent trials with one of the aromatase inhibitors letrozole, including pharmacokinetic and pharmacodynamic data as well as recent data on relative benefits and side effects compared with other available hormonal agents. Relevant ongoing clinical-translational trials evaluating this agent are also discussed.

Original languageEnglish (US)
Pages (from-to)1965-1975
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume8
Issue number12
DOIs
StatePublished - Aug 2007

Fingerprint

letrozole
Aromatase Inhibitors
Art Therapy
Breast Neoplasms
Tamoxifen
Pharmacokinetics
Clinical Trials
Hormones
Therapeutics

Keywords

  • Ajuvant therapy
  • Anti-estrogens
  • Aromatase inhibitor
  • Breast cancer
  • Letrozole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Letrozole : Present and future role in the treatment of breast cancer. / Amar, Surabhi; Roy, Vivek; Perez, Edith A.

In: Expert Opinion on Pharmacotherapy, Vol. 8, No. 12, 08.2007, p. 1965-1975.

Research output: Contribution to journalArticle

Amar, Surabhi ; Roy, Vivek ; Perez, Edith A. / Letrozole : Present and future role in the treatment of breast cancer. In: Expert Opinion on Pharmacotherapy. 2007 ; Vol. 8, No. 12. pp. 1965-1975.
@article{5cb9f77115f74c36a79c2420820f2e8b,
title = "Letrozole: Present and future role in the treatment of breast cancer",
abstract = "State of the art hormonal therapy for women with breast cancer has evolved over the last few years. Tamoxifen used to be the gold standard for adjuvant treatment of postmenopausal women with hormone-sensitive early breast cancer and also for patients with metastatic disease in whom hormonal manipulation was considered, but the introduction of third generation aromatase inhibitors has changed this concept. This article discusses the clinical implications of recent trials with one of the aromatase inhibitors letrozole, including pharmacokinetic and pharmacodynamic data as well as recent data on relative benefits and side effects compared with other available hormonal agents. Relevant ongoing clinical-translational trials evaluating this agent are also discussed.",
keywords = "Ajuvant therapy, Anti-estrogens, Aromatase inhibitor, Breast cancer, Letrozole",
author = "Surabhi Amar and Vivek Roy and Perez, {Edith A.}",
year = "2007",
month = "8",
doi = "10.1517/14656566.8.12.1965",
language = "English (US)",
volume = "8",
pages = "1965--1975",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Letrozole

T2 - Present and future role in the treatment of breast cancer

AU - Amar, Surabhi

AU - Roy, Vivek

AU - Perez, Edith A.

PY - 2007/8

Y1 - 2007/8

N2 - State of the art hormonal therapy for women with breast cancer has evolved over the last few years. Tamoxifen used to be the gold standard for adjuvant treatment of postmenopausal women with hormone-sensitive early breast cancer and also for patients with metastatic disease in whom hormonal manipulation was considered, but the introduction of third generation aromatase inhibitors has changed this concept. This article discusses the clinical implications of recent trials with one of the aromatase inhibitors letrozole, including pharmacokinetic and pharmacodynamic data as well as recent data on relative benefits and side effects compared with other available hormonal agents. Relevant ongoing clinical-translational trials evaluating this agent are also discussed.

AB - State of the art hormonal therapy for women with breast cancer has evolved over the last few years. Tamoxifen used to be the gold standard for adjuvant treatment of postmenopausal women with hormone-sensitive early breast cancer and also for patients with metastatic disease in whom hormonal manipulation was considered, but the introduction of third generation aromatase inhibitors has changed this concept. This article discusses the clinical implications of recent trials with one of the aromatase inhibitors letrozole, including pharmacokinetic and pharmacodynamic data as well as recent data on relative benefits and side effects compared with other available hormonal agents. Relevant ongoing clinical-translational trials evaluating this agent are also discussed.

KW - Ajuvant therapy

KW - Anti-estrogens

KW - Aromatase inhibitor

KW - Breast cancer

KW - Letrozole

UR - http://www.scopus.com/inward/record.url?scp=34548203908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548203908&partnerID=8YFLogxK

U2 - 10.1517/14656566.8.12.1965

DO - 10.1517/14656566.8.12.1965

M3 - Article

C2 - 17696797

AN - SCOPUS:34548203908

VL - 8

SP - 1965

EP - 1975

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -